Skip to content
Lower risk Drug recall · FDA · Published May 5, 2020

Mylan Aloprim Injection Vials May Discolor - Recall for Appearance Issues

Mylan recalls Aloprim (allopurinol sodium) injection vials that may discolor during shelf life due to appearance issues. Affected vials have specific lot numbers and expiration dates. Consumers should check their vials and contact Mylan if unsure.

🇺🇸 FDA recall #D-1271-2020DrugMylan Institutional ›
Take action

Contact the company

Recalling firmMylan Institutional LLC4901 Hiawatha Dr · Rockford, IL 61103-1287
✎ GovInfoNow plain-language explainer

Mylan is recalling Aloprim (allopurinol sodium) injection vials that may discolor by the end of their shelf life. This discoloration is a quality issue detected during routine testing but does not indicate a safety hazard. The recall does not require immediate action beyond checking the vial's expiration date and lot number. Read more at govinfonow.com/recall/37130-mylan-aloprim-injection-vials-may-discolor-recall-for-appearance-issues.

Source Summary by GovInfoNow · govinfonow.com/recall/37130-mylan-aloprim-injection-vials-may-discolor-recall-for-appearance-issues · Updated October 5, 2026 · FDA enforcement record: FDA #D-1271-2020

Cite this page

“Mylan Aloprim Injection Vials May Discolor - Recall for Appearance Issues.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/37130-mylan-aloprim-injection-vials-may-discolor-recall-for-appearance-issues. Based on FDA recall #D-1271-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1271-2020%22&limit=1).

The FDA announced on May 5, 2020, that Mylan Institutional LLC voluntarily recalled Aloprim (allopurinol sodium) for Injection due to discoloration risks. The recall affects 3,010 vials distributed nationwide.

How to tell if you have it

  • Brand: Mylan Institutional
  • Product: Aloprim (allopurinol sodium) for Injection, 500 mg Single-Dose Vial
  • NDC: 67457-187-50
  • Lot #: Lot N1700771, EXP October 2020; Lot N1800127, EXP February 2021

The hazard

The recall was initiated because routine stability testing at the end of shelf-life revealed out-of-specification results for appearance and color of solution. The FDA classified this as a Class II recall.

Context

GovInfoNow's records show Mylan Institutional LLC has 10 other recalls on record since January 23, 2015. Other recent recalls include the May 3, 2021 Mylan Thiamine HCl Injection Recall for incorrect lot/exp dates, the August 17, 2020 Mylan Amiodarone Injection Recall for label mix-up risk, and the July 7, 2020 Mylan Daptomycin Injection Recall for particulate matter hazard. Other recent recalls of similar products include the August 17, 2026 Mylan Prasugrel Tablets Recall for failed stability testing risk, the July 2, 2026 Mylan Mycophenolate Mofetil Injection Recall for precipitate risk, and the July 29, 2026 Shilpa Medicare PEMRYDI RTU Injections recall due to green discoloration.

How to tell if you have this one

Check for Aloprim (allopurinol sodium) injection vials with NDC 67457-187-50. Look for lot numbers N1700771 (expiring October 2020) or N1800127 (expiring February 2021).

  • Brand
    Mylan Institutional
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Vial Expiration

    Verify the expiration date on the vial label to ensure it matches the recalled lots (October 2020 or February 2021).

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Distributed Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 21 months after the firm started it.

1. Firm started the recall: May 5, 202012. FDA classified it Class II: May 20, 202023. Published in FDA’s Enforcement Report: May 27, 202034. FDA terminated the recall: Jan 26, 2022420202022
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1271-2020 (May 5, 2020) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1271-2020 to see it in context.
  • Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA